Treatment of patients with high-grade non-Hodgkin's lymphoma aged over 70 years with an all-oral regimen combining idarubicin, etoposide and alkylators.

[1]  F. Pannuti,et al.  Low dose oral administration of 4-demethoxy-daunorubicin (idarubicin) in advanced cancer patients , 1986, Cancer Chemotherapy and Pharmacology.

[2]  M. Gobbi,et al.  Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. , 1999, Blood.

[3]  H. Gómez,et al.  Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Quaglino,et al.  Therapeutic management of hematological malignancies in elderly patients. Biological and clinical considerations , 1998, Aging.

[5]  M Van Glabbeke,et al.  CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Crivellari,et al.  Pharmacology of chronic oral daily administration of idarubicin. , 1997, Haematologica.

[7]  N. Russell,et al.  The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy , 1997, Leukemia.

[8]  M. Gobbi,et al.  Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. , 1997, Blood.

[9]  正法 梅田,et al.  85歳以上の高齢者非ホジキンリンパ腫に対する etoposide 少量持続経口投与の検討 , 1997 .

[10]  Anderson,et al.  Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  G. Castoldi.  Recent advances in the cytobiology of leukemias. , 1997, Haematologica.

[12]  A. Mileti,et al.  ASSOCIAZIONE DI IDARUBICINA E PREDNIMUSTINE. STUDIO PRELIMINARE DI 25 PAZIENTI CON LINFOMA NON HODGKIN IN STADIO AVANZATO DI MALATTIA , 1994 .

[13]  P. Koistinen,et al.  Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group. , 1994, Leukemia.

[14]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[15]  V. Chiarion-Sileni,et al.  A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  F. d'Amore,et al.  Original article: Non-Hodgkin's lymphoma in the elderly A study of 602 patients aged 70 or older from a Danish population-based registry , 1992 .

[17]  F. d'Amore,et al.  Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-Study Group. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  S. Monfardini,et al.  A Phase II Study of Oral Idarubicin (4‐Demethoxidaunorubicin) in Previously Untreated Elderly Patients with Non‐Hodgkin's Lymphoma , 1991, American journal of clinical oncology.

[19]  R. Gams,et al.  Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma. , 1990, Cancer research.

[20]  P. Sonneveld,et al.  Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen. , 1990, British Journal of Cancer.

[21]  J. Robert,et al.  Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients. , 1990, Leukemia.

[22]  K. Lennert,et al.  Updated Kiel classification for lymphomas , 1989, The Journal of pathology.

[23]  K. K. Rasmussen,et al.  Cardiovascular effects of doxorubicin (Adriamycin) and 4-demethoxydaunorubicin (Idarubicin) in the conscious rat. , 1988, Pharmacology & toxicology.